Status:
COMPLETED
Registry of Etanercept Use in Patients With Rheumatoid Arthritis in Clinical Practice in Taiwan
Lead Sponsor:
Pfizer
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
20+ years
Brief Summary
The purpose of this study is to develop a registry with safety and efficacy data on the use of etanercept in clinical practice in Taiwan.
Eligibility Criteria
Inclusion
- Main 1) Male or female patients aged \> 20 years; 2) Patients who have already been selected and approved under the Taiwan National Health Insurance Program to receive 24 weeks of etanercept for rheumatoid arthritis. Main
Exclusion
Key Trial Info
Start Date :
December 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
441 Patients enrolled
Trial Details
Trial ID
NCT00888576
Start Date
December 1 2008
End Date
December 1 2011
Last Update
February 8 2012
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Changhua, Changhua County, Taiwan, 500
2
Pfizer Investigational Site
Changhua, Changhua, Taiwan, 500
3
Pfizer Investigational Site
Lukang Zhen, Changhua, Taiwan, 50544
4
Pfizer Investigational Site
Dalin, Chia-Yi, Taiwan, 622